Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tumor Suppressor Protein p53 | 9 | 2023 | 89 | 3.780 |
Why?
|
Proto-Oncogene Proteins c-akt | 8 | 2022 | 56 | 2.900 |
Why?
|
Imidazoles | 7 | 2019 | 72 | 2.800 |
Why?
|
Drug Resistance, Neoplasm | 8 | 2022 | 75 | 2.790 |
Why?
|
Piperazines | 7 | 2019 | 90 | 2.750 |
Why?
|
Receptors, Estrogen | 6 | 2022 | 58 | 2.710 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2023 | 316 | 2.660 |
Why?
|
Autophagy | 8 | 2022 | 30 | 2.490 |
Why?
|
Antineoplastic Agents | 8 | 2019 | 218 | 2.210 |
Why?
|
Breast Neoplasms | 9 | 2022 | 328 | 2.110 |
Why?
|
Tamoxifen | 4 | 2022 | 30 | 1.920 |
Why?
|
Lung Neoplasms | 4 | 2023 | 625 | 1.810 |
Why?
|
Cell Line, Tumor | 18 | 2022 | 264 | 1.750 |
Why?
|
Cisplatin | 5 | 2022 | 91 | 1.540 |
Why?
|
Apoptosis | 8 | 2019 | 252 | 1.240 |
Why?
|
Carboxypeptidases | 3 | 2022 | 6 | 1.120 |
Why?
|
Jumonji Domain-Containing Histone Demethylases | 3 | 2022 | 6 | 1.110 |
Why?
|
Neoplasms | 2 | 2018 | 245 | 1.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2022 | 100 | 0.930 |
Why?
|
Glycolysis | 3 | 2018 | 20 | 0.880 |
Why?
|
Retinoblastoma-Like Protein p130 | 1 | 2022 | 2 | 0.850 |
Why?
|
Fatty Acids | 1 | 2021 | 38 | 0.820 |
Why?
|
Signal Transduction | 8 | 2022 | 486 | 0.820 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2022 | 184 | 0.820 |
Why?
|
Proto-Oncogene Proteins c-vav | 3 | 2010 | 3 | 0.770 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2021 | 48 | 0.690 |
Why?
|
Insulin Receptor Substrate Proteins | 2 | 2020 | 14 | 0.690 |
Why?
|
Ketoglutaric Acids | 1 | 2018 | 2 | 0.680 |
Why?
|
Ketoglutarate Dehydrogenase Complex | 1 | 2018 | 3 | 0.680 |
Why?
|
ErbB Receptors | 3 | 2010 | 72 | 0.670 |
Why?
|
Sp1 Transcription Factor | 1 | 2018 | 8 | 0.670 |
Why?
|
Proto-Oncogene Proteins c-cbl | 5 | 2010 | 12 | 0.670 |
Why?
|
Humans | 35 | 2023 | 29334 | 0.660 |
Why?
|
Ubiquitin-Protein Ligases | 4 | 2007 | 35 | 0.620 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 4 | 2019 | 29 | 0.610 |
Why?
|
Cell Lineage | 1 | 2015 | 29 | 0.550 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 48 | 0.510 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 28 | 0.500 |
Why?
|
Serine Endopeptidases | 1 | 2014 | 17 | 0.500 |
Why?
|
Sirolimus | 1 | 2014 | 15 | 0.500 |
Why?
|
Protein Kinases | 1 | 2014 | 13 | 0.490 |
Why?
|
Nitric Oxide | 1 | 2014 | 101 | 0.480 |
Why?
|
Proto-Oncogene Proteins | 2 | 2004 | 31 | 0.480 |
Why?
|
Mice | 12 | 2022 | 1608 | 0.470 |
Why?
|
MCF-7 Cells | 3 | 2021 | 17 | 0.470 |
Why?
|
cdc42 GTP-Binding Protein | 2 | 2010 | 4 | 0.460 |
Why?
|
rac1 GTP-Binding Protein | 2 | 2010 | 12 | 0.460 |
Why?
|
rhoA GTP-Binding Protein | 2 | 2009 | 7 | 0.450 |
Why?
|
Mammary Glands, Human | 2 | 2009 | 6 | 0.450 |
Why?
|
Receptors, Glycine | 2 | 2009 | 2 | 0.440 |
Why?
|
Paclitaxel | 2 | 2022 | 74 | 0.430 |
Why?
|
RNA, Small Interfering | 3 | 2019 | 65 | 0.430 |
Why?
|
Enzyme Activation | 5 | 2014 | 114 | 0.420 |
Why?
|
Animals | 16 | 2022 | 4577 | 0.410 |
Why?
|
Cytotoxins | 1 | 2010 | 5 | 0.390 |
Why?
|
Adherens Junctions | 1 | 2010 | 4 | 0.390 |
Why?
|
Epithelial Cells | 2 | 2010 | 86 | 0.390 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 50 | 0.390 |
Why?
|
Cell Movement | 1 | 2010 | 104 | 0.370 |
Why?
|
Cell Proliferation | 1 | 2010 | 201 | 0.370 |
Why?
|
Morphogenesis | 1 | 2009 | 7 | 0.370 |
Why?
|
Osteosarcoma | 3 | 2018 | 29 | 0.360 |
Why?
|
Methylation | 2 | 2019 | 7 | 0.350 |
Why?
|
Histones | 2 | 2019 | 28 | 0.350 |
Why?
|
Ubiquitin | 5 | 2007 | 24 | 0.350 |
Why?
|
Caffeine | 1 | 2009 | 64 | 0.350 |
Why?
|
Cell Survival | 4 | 2019 | 169 | 0.340 |
Why?
|
Triple Negative Breast Neoplasms | 2 | 2020 | 15 | 0.340 |
Why?
|
Cell Cycle Checkpoints | 2 | 2022 | 7 | 0.340 |
Why?
|
Bone Neoplasms | 3 | 2018 | 101 | 0.330 |
Why?
|
Kidney | 1 | 2009 | 173 | 0.320 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 2 | 2018 | 10 | 0.310 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2021 | 18 | 0.300 |
Why?
|
Checkpoint Kinase 1 | 2 | 2019 | 5 | 0.300 |
Why?
|
RNA Interference | 2 | 2019 | 33 | 0.300 |
Why?
|
Retroviridae Proteins, Oncogenic | 2 | 2003 | 2 | 0.290 |
Why?
|
Phosphorylation | 6 | 2016 | 172 | 0.290 |
Why?
|
Gene Knockdown Techniques | 2 | 2018 | 41 | 0.290 |
Why?
|
Cell Line | 6 | 2013 | 299 | 0.290 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 7 | 0.270 |
Why?
|
Nitrogen | 1 | 2004 | 4 | 0.260 |
Why?
|
Soil | 1 | 2004 | 6 | 0.260 |
Why?
|
Receptors, Antigen | 1 | 2004 | 1 | 0.250 |
Why?
|
Oxygen | 2 | 2015 | 85 | 0.250 |
Why?
|
Trastuzumab | 2 | 2022 | 25 | 0.250 |
Why?
|
Histone Deacetylase 1 | 1 | 2023 | 2 | 0.240 |
Why?
|
Retinoblastoma Protein | 1 | 2023 | 10 | 0.240 |
Why?
|
Benzamides | 1 | 2023 | 16 | 0.240 |
Why?
|
Lysosomes | 1 | 2003 | 24 | 0.230 |
Why?
|
Histone Demethylases | 1 | 2022 | 2 | 0.230 |
Why?
|
Lysine | 1 | 2022 | 13 | 0.230 |
Why?
|
Cadherins | 1 | 2022 | 34 | 0.230 |
Why?
|
Estrogen Receptor alpha | 1 | 2022 | 15 | 0.230 |
Why?
|
CD27 Ligand | 1 | 2022 | 2 | 0.220 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2022 | 3 | 0.220 |
Why?
|
Nanoparticles | 1 | 2022 | 10 | 0.220 |
Why?
|
Antigens, CD | 1 | 2022 | 99 | 0.220 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2022 | 18 | 0.220 |
Why?
|
Aurora Kinase A | 1 | 2022 | 2 | 0.210 |
Why?
|
Aurora Kinase B | 1 | 2022 | 2 | 0.210 |
Why?
|
Female | 10 | 2022 | 16202 | 0.210 |
Why?
|
Glioblastoma | 1 | 2022 | 10 | 0.210 |
Why?
|
Oxidation-Reduction | 1 | 2021 | 73 | 0.210 |
Why?
|
Brain Neoplasms | 1 | 2022 | 124 | 0.190 |
Why?
|
Receptor, ErbB-2 | 3 | 2022 | 41 | 0.190 |
Why?
|
Receptor, IGF Type 1 | 2 | 2017 | 18 | 0.180 |
Why?
|
Autophagy-Related Proteins | 1 | 2019 | 2 | 0.180 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 3 | 0.180 |
Why?
|
A549 Cells | 1 | 2018 | 9 | 0.170 |
Why?
|
Pentose Phosphate Pathway | 1 | 2018 | 3 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 28 | 0.160 |
Why?
|
Adenosine | 1 | 2018 | 13 | 0.160 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2017 | 15 | 0.160 |
Why?
|
Mutation | 4 | 2010 | 383 | 0.160 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2009 | 34 | 0.160 |
Why?
|
Receptors, Somatomedin | 1 | 2017 | 4 | 0.160 |
Why?
|
Phospholipase C gamma | 2 | 2007 | 9 | 0.150 |
Why?
|
Epidermal Growth Factor | 2 | 2010 | 29 | 0.150 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 4 | 0.140 |
Why?
|
DNA Mismatch Repair | 1 | 2016 | 6 | 0.140 |
Why?
|
Biological Assay | 1 | 2016 | 9 | 0.140 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2007 | 21 | 0.140 |
Why?
|
Macrolides | 1 | 2015 | 6 | 0.140 |
Why?
|
Caspase 8 | 1 | 2015 | 11 | 0.140 |
Why?
|
Superoxides | 1 | 2015 | 26 | 0.140 |
Why?
|
Chloroquine | 1 | 2015 | 12 | 0.140 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2015 | 31 | 0.140 |
Why?
|
Cellular Senescence | 1 | 2015 | 18 | 0.140 |
Why?
|
Microscopy, Electron | 1 | 2015 | 70 | 0.140 |
Why?
|
Microscopy, Confocal | 1 | 2015 | 117 | 0.130 |
Why?
|
Flow Cytometry | 1 | 2015 | 197 | 0.130 |
Why?
|
Colorectal Neoplasms | 1 | 2016 | 81 | 0.130 |
Why?
|
DNA Methylation | 1 | 2016 | 125 | 0.130 |
Why?
|
Phagosomes | 1 | 2014 | 3 | 0.130 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 21 | 0.130 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2014 | 17 | 0.130 |
Why?
|
Protein Processing, Post-Translational | 1 | 2014 | 36 | 0.130 |
Why?
|
DNA Primers | 1 | 2014 | 51 | 0.130 |
Why?
|
MAP Kinase Signaling System | 1 | 2014 | 40 | 0.120 |
Why?
|
Base Sequence | 1 | 2014 | 134 | 0.120 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2014 | 64 | 0.120 |
Why?
|
DNA Damage | 1 | 2014 | 30 | 0.120 |
Why?
|
Models, Biological | 1 | 2016 | 343 | 0.120 |
Why?
|
Transfection | 3 | 2020 | 125 | 0.120 |
Why?
|
Gene Expression Regulation | 2 | 2007 | 287 | 0.120 |
Why?
|
Cell Adhesion | 2 | 2010 | 43 | 0.120 |
Why?
|
Aniline Compounds | 1 | 2013 | 41 | 0.120 |
Why?
|
Triazoles | 1 | 2013 | 29 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 438 | 0.100 |
Why?
|
Triterpenes | 1 | 2011 | 2 | 0.100 |
Why?
|
Estrogen Antagonists | 1 | 2010 | 3 | 0.100 |
Why?
|
src-Family Kinases | 3 | 2007 | 8 | 0.100 |
Why?
|
Ubiquitination | 1 | 2010 | 9 | 0.100 |
Why?
|
Protein Transport | 1 | 2010 | 38 | 0.100 |
Why?
|
Actins | 1 | 2010 | 47 | 0.100 |
Why?
|
Cytoskeleton | 1 | 2010 | 51 | 0.100 |
Why?
|
Amino Acid Sequence | 1 | 2010 | 193 | 0.100 |
Why?
|
Molecular Sequence Data | 1 | 2010 | 246 | 0.090 |
Why?
|
Cell Line, Transformed | 1 | 2009 | 17 | 0.090 |
Why?
|
Mice, Nude | 3 | 2020 | 34 | 0.090 |
Why?
|
Precancerous Conditions | 1 | 2009 | 22 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 290 | 0.090 |
Why?
|
Urodela | 1 | 2008 | 1 | 0.080 |
Why?
|
Retinal Ganglion Cells | 1 | 2008 | 3 | 0.080 |
Why?
|
Neural Inhibition | 1 | 2008 | 10 | 0.080 |
Why?
|
Glycine | 1 | 2008 | 12 | 0.080 |
Why?
|
Synaptic Transmission | 1 | 2008 | 46 | 0.080 |
Why?
|
RNA, Messenger | 2 | 2013 | 326 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2022 | 25 | 0.080 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 3 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 7 | 0.080 |
Why?
|
Neovascularization, Physiologic | 1 | 2007 | 22 | 0.080 |
Why?
|
Oncogene Protein v-cbl | 2 | 2003 | 2 | 0.070 |
Why?
|
Macrophages, Alveolar | 1 | 2005 | 2 | 0.070 |
Why?
|
Mycobacterium tuberculosis | 1 | 2005 | 18 | 0.070 |
Why?
|
Plant Development | 1 | 2004 | 3 | 0.060 |
Why?
|
Mitochondria | 1 | 2005 | 78 | 0.060 |
Why?
|
Drug Synergism | 2 | 2017 | 63 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2004 | 19 | 0.060 |
Why?
|
China | 1 | 2004 | 58 | 0.060 |
Why?
|
Membrane Potentials | 1 | 2005 | 189 | 0.060 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2004 | 29 | 0.060 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2004 | 148 | 0.060 |
Why?
|
Oncogene Proteins | 1 | 2003 | 7 | 0.060 |
Why?
|
CHO Cells | 1 | 2003 | 12 | 0.060 |
Why?
|
Mice, Knockout | 1 | 2004 | 303 | 0.060 |
Why?
|
Cricetinae | 1 | 2003 | 36 | 0.060 |
Why?
|
Endosomes | 1 | 2003 | 8 | 0.060 |
Why?
|
Embryo, Mammalian | 1 | 2003 | 31 | 0.060 |
Why?
|
Endocytosis | 1 | 2003 | 17 | 0.060 |
Why?
|
Temperature | 1 | 2003 | 76 | 0.060 |
Why?
|
Blotting, Western | 1 | 2003 | 170 | 0.060 |
Why?
|
Fibroblasts | 1 | 2003 | 97 | 0.060 |
Why?
|
Caspase 9 | 1 | 2022 | 12 | 0.060 |
Why?
|
Down-Regulation | 1 | 2003 | 115 | 0.060 |
Why?
|
Caspase 3 | 1 | 2022 | 30 | 0.060 |
Why?
|
Ceramides | 1 | 2022 | 14 | 0.060 |
Why?
|
Gene Expression | 1 | 2003 | 226 | 0.050 |
Why?
|
Molecular Docking Simulation | 1 | 2022 | 2 | 0.050 |
Why?
|
Genistein | 1 | 2022 | 3 | 0.050 |
Why?
|
Protein Binding | 3 | 2007 | 128 | 0.050 |
Why?
|
Structure-Activity Relationship | 2 | 2013 | 45 | 0.040 |
Why?
|
Luciferases | 2 | 2013 | 24 | 0.040 |
Why?
|
Pyrazines | 1 | 2017 | 10 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2020 | 729 | 0.040 |
Why?
|
Reproductive History | 1 | 2017 | 1 | 0.040 |
Why?
|
Receptors, Progesterone | 1 | 2017 | 27 | 0.040 |
Why?
|
Receptor Cross-Talk | 1 | 2016 | 7 | 0.040 |
Why?
|
Population Surveillance | 1 | 2017 | 116 | 0.040 |
Why?
|
Odds Ratio | 1 | 2017 | 284 | 0.030 |
Why?
|
Tyrosine | 2 | 2007 | 23 | 0.030 |
Why?
|
Biomarkers, Tumor | 1 | 2017 | 175 | 0.030 |
Why?
|
Protein Structure, Tertiary | 2 | 2007 | 61 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2017 | 636 | 0.030 |
Why?
|
Computer Simulation | 1 | 2016 | 218 | 0.030 |
Why?
|
Risk Assessment | 1 | 2017 | 678 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2013 | 14 | 0.030 |
Why?
|
Biological Availability | 1 | 2013 | 26 | 0.030 |
Why?
|
Genes, Reporter | 1 | 2013 | 30 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 2013 | 109 | 0.030 |
Why?
|
Administration, Oral | 1 | 2013 | 140 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 2013 | 452 | 0.030 |
Why?
|
Pentacyclic Triterpenes | 1 | 2011 | 1 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2011 | 7 | 0.020 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2011 | 7 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 30 | 0.020 |
Why?
|
Tumor Burden | 1 | 2011 | 28 | 0.020 |
Why?
|
Mice, SCID | 1 | 2011 | 54 | 0.020 |
Why?
|
Rats | 1 | 2013 | 857 | 0.020 |
Why?
|
Quinazolines | 1 | 2011 | 24 | 0.020 |
Why?
|
Young Adult | 1 | 2017 | 1933 | 0.020 |
Why?
|
Male | 2 | 2020 | 15627 | 0.020 |
Why?
|
Risk Factors | 1 | 2017 | 2436 | 0.020 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2011 | 113 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 258 | 0.020 |
Why?
|
rho-Associated Kinases | 1 | 2009 | 6 | 0.020 |
Why?
|
Telomerase | 1 | 2009 | 9 | 0.020 |
Why?
|
Protein Kinase C | 1 | 2009 | 44 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2009 | 75 | 0.020 |
Why?
|
Retina | 1 | 2008 | 12 | 0.020 |
Why?
|
Ligands | 1 | 2007 | 55 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2007 | 6 | 0.020 |
Why?
|
Binding Sites | 1 | 2007 | 73 | 0.020 |
Why?
|
Laminin | 1 | 2007 | 8 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2007 | 19 | 0.020 |
Why?
|
Gene Silencing | 1 | 2007 | 21 | 0.020 |
Why?
|
Drug Combinations | 1 | 2007 | 82 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2007 | 145 | 0.020 |
Why?
|
Collagen | 1 | 2007 | 103 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 145 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2008 | 687 | 0.020 |
Why?
|
Wound Healing | 1 | 2007 | 168 | 0.020 |
Why?
|
Proteoglycans | 1 | 2007 | 337 | 0.020 |
Why?
|
Receptors, Purinergic P2 | 1 | 2005 | 2 | 0.020 |
Why?
|
Cytochromes c | 1 | 2005 | 15 | 0.020 |
Why?
|
Necrosis | 1 | 2005 | 26 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2005 | 40 | 0.020 |
Why?
|
Cyclosporine | 1 | 2005 | 15 | 0.020 |
Why?
|
Molecular Conformation | 1 | 2004 | 15 | 0.020 |
Why?
|
Adult | 1 | 2017 | 8593 | 0.010 |
Why?
|
Vanadates | 1 | 2003 | 3 | 0.010 |
Why?
|
Jurkat Cells | 1 | 2003 | 10 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2003 | 12 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 38 | 0.010 |
Why?
|
Plasmids | 1 | 2003 | 44 | 0.010 |
Why?
|
Models, Genetic | 1 | 2003 | 35 | 0.010 |
Why?
|
Immunoblotting | 1 | 2003 | 57 | 0.010 |
Why?
|
Middle Aged | 1 | 2017 | 9817 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2003 | 251 | 0.010 |
Why?
|
Time Factors | 1 | 2003 | 1614 | 0.010 |
Why?
|